Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The management of life-threatening complications in patients with sickle cell disease (SCD) requires an accurate and reproducible quantification of haemoglobin A (HbA) and S (HbS) with a short turnaround time and 24-7 availability. We propose a novel method for quantifying HbA and HbS using the glycated haemoglobin (HbA1c) assay on a Tosoh HLC-723G8 (G8) analyser in variant mode. HbA and HbS results obtained using our method highly correlated with results obtained using a reference method (r > 0.99 for 124 samples of patients with SCD or sickle cell trait). Our method met laboratory requirements for linearity (coefficient of variation [CV] and bias <5%), between-run and within-run reproducibility (CV <10%) and carryover (<0.5%) over the range of HbS and HbA values expected in a therapeutic context. Using the G8 analyser in variant mode is viable for monitoring HbA and HbS concentrations in dire situations. This method is easy to use, quick (1.6 min per sample), and automatable and produces highly reproducible results without significant bias. Finally, it does not require modifications to the analytical pipeline recommended by the supplier, enabling a 24-7 availability without disrupting routine monitoring of HbA1c in the laboratory.

Download full-text PDF

Source
http://dx.doi.org/10.1002/bmc.5799DOI Listing

Publication Analysis

Top Keywords

sickle cell
12
hba hbs
12
tosoh hlc-723g8
8
variant mode
8
patients sickle
8
cell disease
8
rapid haemoglobin
4
haemoglobin quantification
4
quantification tosoh
4
hlc-723g8 variant
4

Similar Publications

Introduction: In sub-Saharan Africa, the burden of sickle cell disease remains high. With annual sickle cell births of about 150,000, Nigeria is reported to have the highest prevalence of the disease globally. This study aimed to explore the views and perspectives of healthcare professionals regarding access to healthcare services for sickle cell disease.

View Article and Find Full Text PDF

More than pain: Speech, language, neurocognitive, and hearing issues among children with sickle cell disease.

J Natl Med Assoc

September 2025

Communication Equity Outcomes Laboratory, Department of Speech, Language and Hearing Sciences, University of Florida, Gainesville, FL, United States.

Importance: Significant advancements have been made in the management of sickle cell disease (SCD); an inherited blood disorder most prevalent among African Americans. While chronic pain is a hallmark of SCD and has been the primary focus of treatment, contemporary literature highlights the potential presence of developmental issues related to speech, language, neurocognitive, and auditory abilities that are often overlooked in SCD management.

Observations: This paper explores the spectrum of communication-related challenges that specifically affect children with SCD and fall within the scope of practice for speech-language pathologists (SLPs) and audiologists (AUDs).

View Article and Find Full Text PDF

Vaccine Immunity Against Pneumococcus in Children With Sickle Cell Disease: A Retrospective Single-center Study.

Pediatr Infect Dis J

September 2025

Division of General Pediatrics, Department of Pediatrics, Gynecology and Obstetrics, Unit of Immunology, Vaccinology, and Rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Background And Aims: Sickle cell disease (SCD) patients are at a higher risk of pneumococcal invasive diseases. Vaccination is the central strategy for protecting these children, along with penicillin prophylaxis. However, it is unclear how often these children should be revaccinated with pneumococcal vaccines.

View Article and Find Full Text PDF